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Bisphosphonates and Bone diseases: past, present and future 
 
 
 
Bisphosphonates are stable analogues of the naturally-occuring inorganic 
pyrophosphate and unlike PPi, they are resistant to hydrolysis due to a carbon atom bridging 
the two phosphonate groups. Whether the first bisphosphonates formerly termed 
diphosphonates were synthesized in the late 1800s, their clinical applications have been 
relatively recent. In the 1960s, H. Fleisch and R.G.G. Russell identified the inorganic 
pyrophosphate as an important physiological regulator of calcification and with M.D. Francis 
demonstrated that bisphosphonates inhibit the pathological calcifications in vivo [1]. These 
three distinguished researchers will become the leaders of international research on 
bisphosphonates. The first medical use of the bisphosphonate, etidronate disodium, was in 
1968 to treat a young patient suffering from myositis ossificans progressiva. Today, 
bisphosphonates have been widely used during the last 3 decades in the treatment of diseases 
involving excessive bone resorption which include post-menopausal osteoporosis, Paget’s 
disease of bone, tumour-associated bone disease, and hypercalcaemia of malignancy. 
However, it is only in recent years that major advances have been made in our understanding 
of the cellular and molecular mechanisms of action of this class of drugs. The present issue of 
Current Pharmaceutical Design, for which I have the honour to be the Executive Guest Editor,  
will give an overview of the past, the present and the future of bisphosphonates. This special 
issue prepared by specialists of bisphosphonates addresses all aspects of bisphosphonates 
including their pharmacology and chemical evolution, their recent elucidated mechanisms of 
action (in bone and non bone cells), the assessment of their biological activities, their main 
pre-clinical and in fine their main clinical applications. 
The specific pharmacology of nitrogen-containing bisphosphonates (N-BPs) is mainly 
attributable to their calcium adsorption and chelating properties. In agreement with this 
specificity, they primarily affect the function of resorbing osteoclasts but recent advances 
gave some evidences that other cell types (osteoblasts, osteocytes, monocytes, T lymphocytes, 
etc) could be the targets of these drugs. In this context, A. Roelof, K. Thompson, F.H. Ebetino, 
M.J. Rogers, and F.P. Coxon give an overview of the pharmacology of bisphosphonates 
covering their development, molecular mechanisms of action, bone mineral binding properties 
and cellular actions [2]. Once bound to bone the N-BPs can be internalized by osteoclasts 
where the drug can then interact with its molecular target, the Farnesyl Pyrophosphate 
Synthase (FPPS), a key enzyme in the mevalonate pathway. This targeting then prevents the 
prenylation process, disrupts vital signaling and induces the loss of osteoclast activities and 
their death. Recent investigations summarized by J.E. Dunford [3] clarified the biochemistry 
of  FPPS and its inhibition by the N-BPs but also identified many other targets for this drugs 
(other FPPS enzymes, Matrix Metalloproteinases, Protein Tyrosine Phosphatases, etc). These 
new targets lead to the development of a new generation of N-BPs characterized by a low 
affinity to the bone mineral and then can be available to extraosseous targets. These 
observations opened novel clinical applications. FPPS is the main targets of N-BPs, however 
these drugs exert consequently very large effects on cell metabolism affecting cell adhesion, 
migration, division and death. To identify the mechanisms of actions of bisphosphonates, 
novel methodologies have been set up. L.M. Mitrofan, S. Auriola, H. Mönkkönen
 
and J. 
Mönkkönen [4] present an original review which highlights the main methodologies used to 
monitor the action of BPs in in vitro cell models, with a special emphasis on the detection of 
BP-induced ATP-analogues by mass spectrometry. Cell death monitoring, 
immunomodulatory effects and inhibition of growth/proliferation are also described.  
Bisphosphonates have been used successfully for many years to reduce the skeletal 
complications associated with the benign and malignant bone diseases that are characterized 
by enhanced osteoclastic bone resorption. Until recently, it was thought that the clinical 
efficacy of bisphosphonates in the treatment of cancer patients with bone metastases was 
purely a result of the inhibition of osteoclast-mediated bone resorption. However, recent 
studies have demonstrated that bisphosphonates inhibit the growth, attachment and invasion 
of cancer cells in culture and promote their apoptosis. These results suggest that these drugs 
are also anti-cancer agents, raising the possibility that they could inhibit cancer-cell 
colonization in visceral organs. Thus, a series of complementary reviews addressing the 
clinical interest of bisphosphonates in oncology is proposed in the present issue. The first is 
proposed by G. Moriceau, B. Ory, B. Gobin, F. Verrecchia, F. Gouin, F. Blanchard, F. Rédini 
and Heymann D. and describes the clinical applications of bisphosphosnates in the primary 
bone tumors (giant cell tumor of bone, osteosarcoma, Ewing’s sarcoma, chondrosarcoma, 
etc.) [5]. Thus, these drugs have been used as a carrier for radio nucleotides to develop novel 
approaches of bone imaging. They exert also indirect anti-tumour activities in vivo by 
interfering with the bone microenvironment and target osteoclasts, endothelial cells and 
immune cells (tumour-associated macrophages, 92 T cells). They induce tumour cell death 
in vitro and similar activity is suspected in vivo explaining why clinical trials assessing the 
combination conventional chemotherapy with bisphosphonates are actually in progress. In 
contrast to primary bone tumors for which the clinical impact of bisphosphonates is currently 
in progress, bisphosphonates are now a standard treatment for bone metastases.  Pre-clinical 
data demonstrated the anti-tumor effects of bisphosphonates alone and to combine theses 
drugs with other anti-cancer agents. S.P. Syddall, P.D. Ottewell and I. Holen give an overview 
of these pre-clinical studies and of the main clinical studies which aimed to determine 
whether adding bisphosphonates to standard anti-cancer therapy will improve outcome for 
patients [6]. E.J. Woorward and R.E. Coleman have perfectly completed this last review and 
compelled the most recent reported randomised clinical studies to support the use of 
bisphosphonates in clinical practice at earlier stages of the disease to prevent bone metastases 
[7]. Recent data revealed that N-BPs are able to stimulate human T cells and pastes N-BPs 
at the crossroad of innate and adaptive immunity. This new activity of N-BPs strengthens 
their interest as anti-tumour agents through the modulation of immune system. This novel 
activity of N-BPs is summarized by P. Clézardin and M. Massaia in an exhaustive review on 
the molecular and cellular mechanisms by which N-BPs stimulate the expansion and 
cytotoxic activity of human  T cells [8]. They also discuss the emerging clinical evidence 
that N-BPs can have a role in cancer immunotherapy. It will be not objective to focus all 
reviews of this issues to discard the other therapeutic options for the treatment of bone 
metastases excepted N-BPs. The recent better understanding of bone biology lead to the 
elaborations of newer and more and more efficient drugs with requires very stringent clinical 
studies to prove their clinical interest and to determine the long term side-effects. J.T. Buijs, 
CC.H. Kuijpers and G. van der Pluijm described in details the molecular process of metastasis 
from primary tumor to bone through which the novel drugs have been elaborated [9]. These 
authors have checked the novel therapeutic targets (bisphosphonates, RANKL, TGF, Wnt 
pathway,  MMPs, Cathepsin K, integrins, calcium sensing receptor, CXXR5/CXCL12 axis, 
ET-1 pathway, glcycoprotein nonmetastatic B, Src, etc) and the strategies developed for the 
treatment of bone metastases. To complete this very large panel of review on bisphosphonate 
and cancers, M.A. Lawson, J. Ashcroft and P.I. Croucher have proposed a specific review on 
multiple myeloma and bisphosphosnates [10]. Indeed, multiple myeloma is an incurable B 
cell neoplasm often resulting in devastating osteolysis. Bisphosphonates have been 
successfully used to treat the tumour-induced bone disease associated with multiple myeloma. 
Their review focus on preclinical studies and clinical investigations of patients suffering from 
multiple myeloma which have contributed to a better under understanding of the mechanisms 
of action of bisphosphonates in this pathology.  
 Because bisphosphonates currently remain the principle drugs used to treat excessive bone 
resorption, they have extensively used in rheumatology.  The first review on this topic, prepared by  B. 
Le Goff, P. Guillot, J. Glémarec, J.M. Berthelot and Y. Maugars summarize the use of 
bisphosphonates for the treatment of osteoporosis and compared their clinical effects with 
other treatment [11]. They have done an evaluation of the cost of all treatments, topic 
particularly important in the actual health politics. The second review presented by B. Le Goff, 
J.M. Berthelot, Y. Maugars and E. Romas focuses on the new potential alternative indications 
for bisphosphonate in rheumatic diseases [12]. Indeed, bisphosphonates could also have 
others properties through a specific analgesic or anti-inflammatory effect. Thus, rheumatic 
diseases like rheumatoid arthritis, spondylarthritis or SAPHO syndrome that are associated 
with bone loss could be good candidates for bisphosphonate therapy similarly to other non-
inflammatory rheumatic diseases like bone osteonecrosis, algodystrophy, fibrous dysplasia or 
neuropathic osteoarthropathy.  
 
I wish to thank all the authors and co-authors for their commitments and to give their 
expertise to our colleagues, clinician and researchers, to the students and to all readers. I 
would like to thank the anonymous reviewers who contributed by their constructive remarks 
to the excellence of this issue.  
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